David Whittaker

Discovery of a Potent and Selective EGFR Inhibitor (AZD9291) of Both Sensitizing and T790M Resistance Mutations That Spares the Wild Type Form of the Receptor

M. Raymond V. Finlay, Mark J. Anderton, Susan Ashton et al. · Journal of Medicinal Chemistry · 2014 · 602 citations · Full text

Medicine, Oncology, Pharmacology +15

Design and Synthesis of Novel Lactate Dehydrogenase A Inhibitors by Fragment-Based Lead Generation

Richard A. Ward, C. Brassington, Alexander L. Breeze et al. · Journal of Medicinal Chemistry · 2012 · 169 citations · Full text

Pharmacy, Biochemistry, Medicinal Chemistry +17

Potent and selective bivalent inhibitors of BET bromodomains

Michael J. Waring, Huawei Chen, Alfred A. Rabow et al. · Nature Chemical Biology · 2016 · 135 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +12

Optimization of a Series of Bivalent Triazolopyridazine Based Bromodomain and Extraterminal Inhibitors: The Discovery of (3<i>R</i>)-4-[2-[4-[1-(3-Methoxy-[1,2,4]triazolo[4,3-<i>b</i>]pyridazin-6-yl)-4-piperidyl]phenoxy]ethyl]-1,3-dimethyl-piperazin-2-one (AZD5153)

Robert H. Bradbury, Rowena Callis, Gregory R. Carr et al. · Journal of Medicinal Chemistry · 2016 · 86 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +15

Discovery of Pyrazolo[1,5-<i>a</i>]pyrimidine B-Cell Lymphoma 6 (BCL6) Binders and Optimization to High Affinity Macrocyclic Inhibitors

William McCoull, Roman Abrams, Erica Anderson et al. · Journal of Medicinal Chemistry · 2017 · 78 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +17